Small Cell Lung Cancer Treatment Regimens

**Clinical Trials:** The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment.

Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

**Note:** All recommendations are Category 2A unless otherwise indicated.

### Systemic Therapy as Primary or Adjuvant Therapy

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Limited Stage (maximum of 4–6 cycles)</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Cisplatin + Etoposide<sup>a,b</sup> | Day 1: Cisplatin 60mg/m² IV over 60 minutes  
Days 1–3: Etoposide 120mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4-6 cycles.  
OR  
Day 1: Cisplatin 75mg/m² IV over 60 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4–6 cycles  
OR  
Days 1–3: Cisplatin 25mg/m² IV over 60 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4–6 cycles. |
| Carboplatin + Etoposide<sup>5,8</sup> | Day 1: Carboplatin AUC 5–6 IV over 30 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4–6 cycles. |

| **Extensive Stage (maximum of 4–6 cycles)** |
| Carboplatin/Etoposide + Atezolizumab (Category 1: preferred)<sup>9,10,a</sup> | Day 1: Carboplatin AUC 5 IV over 30 minutes  
Day 1: Atezolizumab 1,200mg IV. Repeat cycle every 3 weeks for 4 cycles.  
Day 1: Atezolizumab 1,200mg IV. Repeat cycle every 3 weeks. |
| Carboplatin + Etoposide<sup>5,8,a</sup> | Day 1: Carboplatin AUC 5–6 IV over 30 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4–6 cycles. |
| Cisplatin + Etoposide<sup>6,11,13,a</sup> | Day 1: Cisplatin 75mg/m² IV over 60 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4–6 cycles.  
OR  
Day 1: Cisplatin 80mg/m² IV over 60 minutes  
Days 1–3: Etoposide 80mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4–6 cycles.  
OR  
Days 1–3: Cisplatin 25mg/m² IV over 60 minutes  
Days 1–3: Etoposide: 100mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4–6 cycles. |
| Carboplatin + Irinotecan<sup>5,14,a</sup> | Day 1: Carboplatin AUC 5 IV over 30 minutes  
Days 1, 8, and 15: Irinotecan 50mg/m² IV over 90 minutes. Repeat cycle every 4 weeks for 4–6 cycles. |
| Cisplatin + Irinotecan<sup>5,15,16,a</sup> | Day 1: Cisplatin 60mg/m² IV over 60 minutes  
Days 1, 8, and 15: Irinotecan 60mg/m² IV over 90 minutes. Repeat cycle every 4 weeks for 4 cycles.  
OR  
Day 1 and 8: Cisplatin 30mg/m² IV over 60 minutes  
Day 1 and 8: Irinotecan 65mg/m² IV over 90 minutes. Repeat cycle every 3 weeks for 4–6 cycles. |

continued
# Small Cell Lung Cancer Treatment Regimens

## Subsequent Systemic Therapy\(^{1,a,f}\)

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOISING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Relapse ≤6 months, PS 0-2(^1)</strong></td>
<td></td>
</tr>
<tr>
<td>Topotecan(^{17,19})</td>
<td><strong>Days 1–5:</strong> Topotecan 1.5mg/m(^2) IV daily over 30 minutes. Repeat cycle every 3 weeks. <strong>OR</strong> <strong>Days 1–5:</strong> Topotecan 2.3mg/m(^2) orally once daily. Repeat cycle every 3 weeks.</td>
</tr>
<tr>
<td>Irinotecan(^{20})</td>
<td><strong>Days 1,8,15,22:</strong> Irinotecan 100mg/m(^2) IV over 90 minutes. Repeat cycle every 4 weeks.</td>
</tr>
<tr>
<td>Paclitaxel(^{21,22})</td>
<td><strong>Day 1:</strong> Paclitaxel 175mg/m(^2) IV over 3 hours. Repeat cycle every 3 weeks. <strong>OR</strong> <strong>Days 1,8,15,22,29,36:</strong> Paclitaxel 80mg/m(^2) IV over 60 minutes. Repeat cycle every 8 weeks (6 weeks on followed by 2 weeks off).</td>
</tr>
<tr>
<td>Docetaxel(^{23})</td>
<td><strong>Day 1:</strong> Docetaxel 60-100 mg/m(^2) IV over 60 minutes. Repeat cycle every 3 weeks.</td>
</tr>
<tr>
<td>Temozolomide(^{24,25})</td>
<td><strong>Days 1–21:</strong> Temozolomide 75mg/m(^2) orally once daily. Repeat cycle every 4 weeks. <strong>OR</strong> <strong>Days 1–5:</strong> Temozolomide 200mg/m(^2) orally once daily. Repeat cycle every 4 weeks.</td>
</tr>
<tr>
<td>Nivolumab(^{26,28})</td>
<td><strong>Day 1:</strong> Nivolumab 240mg IV over 30 minutes Repeat cycle every 2 weeks. <strong>OR</strong> <strong>Day 1:</strong> Nivolumab 480mg IV over 30 minutes Repeat cycle every 4 weeks.</td>
</tr>
<tr>
<td>Nivolumab + Ipilimumab(^{26,29})</td>
<td><strong>Day 1:</strong> Nivolumab 1mg/kg IV over 30 minutes <strong>Day 1:</strong> Ipilimumab 3mg/kg IV over 90 minutes Repeat cycle every 3 weeks for 4 cycles, <strong>followed by:</strong> <strong>Day 1:</strong> Nivolumab 240mg IV over 30 minutes. Repeat cycle every 2 weeks. <strong>OR</strong> <strong>Day 1:</strong> Nivolumab 1mg/kg IV over 30 minutes <strong>Day 1:</strong> Ipilimumab 3mg/kg IV over 90 minutes Repeat cycle every 3 weeks for 4 cycles, <strong>followed by:</strong> <strong>Day 1:</strong> Nivolumab 480mg IV over 30 minutes. Repeat cycle every 4 weeks.</td>
</tr>
<tr>
<td>Pembrolizumab(^{30-32})</td>
<td><strong>Day 1:</strong> Pembrolizumab 200mg IV over 30 minutes. Repeat cycle every 3 weeks.</td>
</tr>
<tr>
<td>Vinorelbine(^{33,34})</td>
<td><strong>Days 1, 8, 15:</strong> Vinorelbine 25–30mg/m(^2) IV over 5-10 minutes. Repeat cycle every 3 weeks.</td>
</tr>
<tr>
<td>Oral Etoposide(^{35,36})</td>
<td><strong>Days 1–21:</strong> Etoposide 50mg/m(^2) orally once daily. Repeat cycle every 4 weeks.</td>
</tr>
<tr>
<td>Gemcitabine(^{37,38})</td>
<td><strong>Days 1, 8, and 15:</strong> Gemcitabine 1,000mg/m(^2) IV over 30 minutes. Repeat cycle every 4 weeks.</td>
</tr>
<tr>
<td>Cyclophosphamide + Doxorubicin + Vincristine (CAV)(^{39})</td>
<td><strong>Day 1:</strong> Cyclophosphamide 1,000mg/m(^2) IV over 60 minutes <strong>Day 1:</strong> Doxorubicin 45mg/m(^2) IV push <strong>Day 1:</strong> Vincristine 2mg IV over 5-10 minutes. Repeat cycle every 3 weeks.</td>
</tr>
<tr>
<td>Bendamustine (Category 2B)(^{19})</td>
<td><strong>Days 1 and 2:</strong> Bendamustine 120mg/m(^2) IV over 10 minutes or 60 minutes (based on product selection). Repeat cycle every 3 weeks for 6 cycles.</td>
</tr>
<tr>
<td><strong>Relapse &gt;6 months(^{1})</strong></td>
<td></td>
</tr>
<tr>
<td>Original regimen(^{46})</td>
<td></td>
</tr>
</tbody>
</table>

---

\(^{1}\) Continued

---

CancerTherapyAdvisor.com
Small Cell Lung Cancer Treatment Regimens

The regimens included are representative of the more commonly used regimens for small cell lung cancer. Other regimens may be acceptable.

Regimen is not recommended for relapsed disease in patients on maintenance atezolizumab at time of relapse. For patients who relapse after >6 months of atezolizumab in maintenance therapy, recommend re-treatment with carboplatin + etoposide alone.

During systemic therapy + radiotherapy, cisplatin/etoposide is recommended (category 1).

Therapy is not recommended for relapsed disease in patients on maintenance atezolizumab at time of relapse. For patients who relapse after >6 months of atezolizumab in maintenance therapy, recommend re-treatment with carboplatin + etoposide alone.

Subsequent systemic therapy refers to second-line and beyond therapy.

References